Bayer Seeks To Ward Off Xarelto Infringers In India
Executive Summary
Bayer presses on with legal action to fend off alleged infringers of its patent on Xarelto in India. A hearing is expected shortly in one such case, which seemingly includes a settlement option. The German multinational also remains engaged in a keenly contested and controversial case around India’s Bolar exemption provision - the experimental use or early working exception.
You may also be interested in...
Indian Court Rebuffs Bayer In Bolar Exemption Case
The Delhi High Court has rejected Bayer’s contention around certain key aspects of India’s Bolar provision – the experimental use or early working exception – and held that “sale” both within the country and abroad is permitted under these norms, subject to certain conditions.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Merck KGaA Exec On Innovating Vaccine Manufacturing To Tackle Outbreaks
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Need a specific report? 1000+ reports available
Buy Reports